TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC	Bone Diseases, Developmental, Camurati-Engelmann disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, bone disorder, carcinoma, epithelial neoplasm, hereditary disease, musculoskeletal system disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, osteochondrodysplasia, otorhinolaryngologic disease	Active, not recruiting	Phase 1	2026-01-29		NCT02065362

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Baylor College of Medicine	267
Center for Cell and Gene Therapy, Baylor College of Medicine	40
National Cancer Institute (NCI)	3015
The Methodist Hospital Research Institute	124

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Texas Children's Hospital	Houston	United States	187